Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Sponsored By
Series
Series
A Dose Escalation Strategy for HR+/HER2− Early Breast Cancer: An Educational Video Series
Multiple Myeloma Education
ESMO Early Breast Cancer
ADC Therapy Treatment HER2+ and HER2-Low mBC
IWTI Best Practices in GU Navigation
Antibody Drug Conjugate Therapy for the Treatment of HER2+ and HER2-Low mBC
ESMO Early Breast Cancer
ESMO Early Breast Cancer
Interview with the Innovators
Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer
Nadia Harbeck, MD, PhD
Read More
ESMO Early Breast Cancer
Interview with the Innovators
New Developments on Prognostic Markers for Patients With Early Breast Cancer
Nadia Harbeck, MD, PhD
Read More
ESMO Early Breast Cancer
Interview with the Innovators
Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer
Nadia Harbeck, MD, PhD
Read More
Results 1 - 3 of 3
